George Scangos, Vir
March 12, 2020 09:21 AM EDTUpdated 12:32 PM
People
R&D

Vir’s George Scan­gos teams up with his for­mer col­leagues at Bio­gen to press fast-for­ward on an­ti­body pro­grams for coro­n­avirus

John Carroll

Editor & Founder

Vir CEO George Scan­gos is in hot pur­suit of some an­ti­bod­ies that can com­bat coro­n­avirus. And he’s turned to one big shop he knows well to cov­er the man­u­fac­tur­ing end of that strat­e­gy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK ac­cus­es Pfiz­er and BioN­Tech of mR­NA patent in­fringe­ment

Bris­tol My­ers out­lines ‘about 12’ pipeline cuts as it ex­e­cutes ma­jor cut­backs

Up­dat­ed: Bris­tol My­ers plans $1.5B in cost cuts, in­clud­ing 2,200 jobs, as CEO promis­es more ‘ag­ile’ com­pa­ny

De­spite on­col­o­gy cut­backs, Sanofi isn’t out of the game yet with ear­ly as­sets

Mer­ck KGaA to ex­pand Ger­man head­quar­ters with €300M+ re­search cen­ter 

Drug and biotech com­pa­nies join lob­by­ing push on Chi­na bill as scruti­ny of WuXi con­tin­ues

A service from the Financial Times